Quick Answer
BridgeBio Pharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $570.12 million for the year ending 2025.
- BridgeBio Pharma, Inc. showed a decrease of -16.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $211.73 million | Q1 2019: $373.03 million | Q2 2019: $293.80 million | Q3 2019: $413.97 million | Q1 2020: $757.05 million | Q2 2020: $540.92 million | Q3 2020: $366.97 million | Q1 2021: $471.18 million | Q2 2021: $378.42 million | Q3 2021: $180.35 million | Q1 2022: $371.55 million | Q2 2022: $470.10 million | Q3 2022: $483.24 million | Q1 2023: $407.37 million | Q2 2023: $302.44 million | Q3 2023: $505.21 million | Q1 2024: $475.22 million | Q2 2024: $407.96 million | Q3 2024: $266.32 million | Q1 2025: $540.60 million | Q2 2025: $748.95 million | Q3 2025: $642.95 million.
- Over the full 9 years of available data (2017 to 2025), BridgeBio Pharma, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 519.7%.
- Historical annual values: Fiscal year 2025: $570.12 million | Fiscal year 2024: $681.10 million | Fiscal year 2023: $375.94 million | Fiscal year 2022: $376.69 million | Fiscal year 2021: $393.77 million | Fiscal year 2020: $356.08 million | Fiscal year 2019: $363.77 million | Fiscal year 2018: $436.09 million | Fiscal year 2017: $92.00 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: